AbbVie, a research-based global biopharmaceutical company, and Allergan plc, a global pharmaceutical company, have shared that the U.S. Federal Trade Commission (FTC) has accepted the proposed consent order in connection with AbbVie’s pending acquisition of Allergan.   The acceptance by the FTC satisfies all required antitrust clearances needed to be obtained for the acquisition of Allergan by AbbVie.   As part of the proposed consent, Allergan has agreed to divest brazikumab, an investiga...